

Disclosures

Personal Commercial (4)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amgen Inc.	Research/Research Grants ‡ EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction	Significant (>= \$5,000)	Prevention
Arrowhead Pharmaceuticals, Inc.	Research/Research Grants	Modest (< \$5,000)	Prevention
Eli Lilly and Company	Research/Research Grants ‡ Site PI: ACCLAIM-Lp(a)	Significant (>= \$5,000)	Prevention
Novartis Pharmaceuticals	Research/Research Grants ‡ Site PI: CTQJ230A12301: (HORIZON) ; Site PI: [Lp(a)FRONTIERS CAVS]; Site PI: (EXPANSION)	Significant (>= \$5,000)	Prevention

Additional Personal Commercial Disclosures for Education Activities (1)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Wake Forest School of Medicine	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (1)

Trial Name	Trial Sponsor	Trial Funding Source
Cascade Screening for Awareness and Detection of Familial Hypercholesterolemia (CASCADE)	The FH Foundation	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 6/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 6/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 6/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 6/1/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members

involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.